Russell Investments Group Ltd. Purchases 728,381 Shares of Bristol Myers Squibb Company $BMY

Russell Investments Group Ltd. lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 24.8% in the third quarter, Holdings Channel.com reports. The firm owned 3,669,050 shares of the biopharmaceutical company’s stock after purchasing an additional 728,381 shares during the quarter. Russell Investments Group Ltd.’s holdings in Bristol Myers Squibb were worth $165,107,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of BMY. CVA Family Office LLC lifted its position in Bristol Myers Squibb by 2.6% in the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock worth $404,000 after buying an additional 223 shares during the last quarter. MSH Capital Advisors LLC grew its position in Bristol Myers Squibb by 2.9% during the third quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company’s stock valued at $362,000 after acquiring an additional 223 shares during the last quarter. Bell & Brown Wealth Advisors LLC raised its stake in shares of Bristol Myers Squibb by 0.5% during the third quarter. Bell & Brown Wealth Advisors LLC now owns 42,691 shares of the biopharmaceutical company’s stock worth $1,925,000 after acquiring an additional 224 shares in the last quarter. Addison Advisors LLC raised its stake in shares of Bristol Myers Squibb by 6.2% during the third quarter. Addison Advisors LLC now owns 3,972 shares of the biopharmaceutical company’s stock worth $179,000 after acquiring an additional 232 shares in the last quarter. Finally, Mccarter Private Wealth Services LLC lifted its holdings in shares of Bristol Myers Squibb by 5.0% in the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock worth $222,000 after acquiring an additional 235 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Down 0.9%

NYSE:BMY opened at $60.21 on Monday. The firm has a market capitalization of $122.62 billion, a P/E ratio of 17.45, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company has a fifty day moving average of $57.66 and a 200 day moving average of $51.03. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. FDA approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis — a label expansion that can broaden Sotyktu’s market opportunity and revenue runway. U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
• Positive Sentiment: BMY declared a quarterly dividend of $0.63/share (ex-dividend April 2), maintaining a high-yield payout that supports income-focused investors and can underpin the stock’s valuation. Dividend Announcement
• Positive Sentiment: Reblozyl showed positive Phase 2 results in alpha-thalassemia and has exceeded $2.3B in annualized sales — evidence Reblozyl is becoming a material growth driver as older drugs decline. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Bristol-Myers Squibb is tracking the real-world impact of KarXT in schizophrenia — useful clinical/market data but longer-term and unlikely to move near-term earnings. Bristol-Myers Squibb Tracks Real-World Impact of KarXT in Schizophrenia
• Negative Sentiment: Q4 results showed revenue roughly in line but EPS missed consensus (reported $1.26 vs. ~$1.65 expected), which prompted investor selling and weighed on the stock. Earnings and Market Reaction
• Negative Sentiment: Recent articles highlight a larger-than-market intraday decline and analyst focus on legacy-product pressures — shorter-term sentiment and volatility remain a risk until new product growth scales. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market

Analyst Upgrades and Downgrades

BMY has been the topic of several recent research reports. HSBC reaffirmed a “hold” rating and set a $53.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price target for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Barclays started coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Finally, Piper Sandler reissued an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $61.00.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.